We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-10.95%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.5B
AUM Growth
-$293M
(-11%)
Cap. Flow
-$295M
Cap. Flow
% of AUM
-11.83%
Top 10 Holdings %
Top 10 Hldgs %
36.69%
Holding
119
New
16
Increased
26
Reduced
20
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
|
+$120M |
| 2 |
Viatris
VTRS
|
+$32.1M |
| 3 |
Vericel Corp
VCEL
|
+$31.5M |
| 4 |
AGN
Allergan plc
AGN
|
+$29.5M |
| 5 |
Aclaris Therapeutics
ACRS
|
+$28.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DBVT
DBV Technologies
DBVT
|
+$65.1M |
| 2 |
ECYT
Endocyte, Inc. Common Stock
ECYT
|
+$62.4M |
| 3 |
Acadia Healthcare
ACHC
|
+$27.8M |
| 4 |
Agios Pharmaceuticals
AGIO
|
+$26.9M |
| 5 |
Regenxbio
RGNX
|
+$20.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 69.79% |
| 2 | Financials | 1.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $133M | 5.34% |
6,825,719
+215,825
| +3% | +$4.23M |
|
|
ORTX
2
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $126M | 5.05% |
+802,360
| New | +$120M |
|
3
Q32 Bio
QTTB
$255M
| $117M | 4.68% |
290,391
| – | – |
|
|
4
Viatris
VTRS
$20.1B
| $77.6M | 3.11% |
2,833,741
+991,630
| +54% | +$32.1M |
|
|
5
Vericel Corp
VCEL
$2.38B
| $64.8M | 2.6% |
3,725,900
+2,108,170
| +130% | +$31.5M |
|
|
XLRN
6
DELISTED
Acceleron Pharma
XLRN
| $60.4M | 2.42% |
1,386,541
+268,890
| +24% | +$13.4M |
|
|
XENT
7
DELISTED
Intersect ENT, Inc
XENT
| $58.6M | 2.34% |
2,078,375
-69,575
| -3% | -$2.04M |
|
8
BioCryst Pharmaceuticals
BCRX
$2.36B
| $55.8M | 2.23% |
6,910,789
| – | – |
|
|
AERI
9
DELISTED
Aerie Pharmaceuticals
AERI
| $54.8M | 2.19% |
1,518,596
-21,852
| -1% | -$1.03M |
|
|
MYOK
10
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $48.7M | 1.95% |
997,000
+80,000
| +9% | +$4.4M |
|
11
AnaptysBio
ANAB
$1.72B
| $47.4M | 1.9% |
743,439
+95,973
| +15% | +$7.14M |
|
12
argenx
ARGX
$53.8B
| $45.3M | 1.82% |
472,000
-184,500
| -28% | -$16.4M |
|
|
13
Aclaris Therapeutics
ACRS
$793M
| $43.6M | 1.74% |
5,893,416
+2,800,000
| +91% | +$28.9M |
|
14
Xeris Biopharma Holdings
XERS
$1.52B
| $42.5M | 1.7% |
2,498,666
| – | – |
|
15
eHealth
EHTH
$47.3M
| $41.4M | 1.66% |
1,076,402
-150,659
| -12% | -$5.07M |
|
16
Universal Health Services
UHS
$9.15B
| $38.7M | 1.55% |
332,000
+70,000
| +27% | +$8.8M |
|
17
Sarepta Therapeutics
SRPT
$1.82B
| $37.3M | 1.49% |
341,800
+45,800
| +15% | +$5.73M |
|
18
CALL
CVS Health
CVS
$137B
| $37.1M | 1.49% |
566,800
| – | – |
|
|
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $37.1M | 1.48% |
874,486
+33,575
| +4% | +$1.34M |
|
|
NVRO
20
DELISTED
NEVRO CORP.
NVRO
| $35.6M | 1.42% |
914,273
+389,233
| +74% | +$17.3M |
|
21
Centene
CNC
$32.8B
| $33M | 1.32% |
572,000
+82,000
| +17% | +$5.49M |
|
|
PTLA
22
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $32.7M | 1.31% |
1,677,414
-778,172
| -32% | -$16M |
|
23
Kiniksa Pharmaceuticals
KNSA
$4.92B
| $31.7M | 1.27% |
1,128,822
+66,866
| +6% | +$1.4M |
|
24
Ascendis Pharma A/S
ASND
$17.1B
| $31.6M | 1.27% |
505,098
+185,098
| +58% | +$11.6M |
|
|
DPLO
25
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $31.6M | 1.27% |
2,348,993
+1,495,306
| +175% | +$25.2M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q4 2018 Portfolio in Review
As of Q4 2018, Deerfield Management held 119 positions worth $2.5B, down 11% from $2.79B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Deerfield Management withdrew a net $295M in Q4 2018, closing 21 positions and reducing 20 holdings. Its most notable exit was DBV Technologies, an estimated $65.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 69% a quarter earlier, followed by Financials.
Against the trend, Deerfield Management opened a new position in Orchard Therapeutics plc American Depositary Shares worth $126M.
- Deerfield Management's largest Q4 2018 buy was Orchard Therapeutics plc American Depositary Shares: 802,360 shares worth $126M.
- Deerfield Management added most to Viatris in Q4 2018, an estimated $32.1M increase.
- Deerfield Management's biggest Q4 2018 reduction was Acadia Healthcare, cutting an estimated $27.8M.
- Deerfield Management fully exited DBV Technologies in Q4 2018, selling an estimated $65.1M.
- Deerfield Management's ten largest holdings make up 37% of its $2.5B portfolio in Q4 2018.
- Deerfield Management opened 16 new positions and closed 21 in Q4 2018.
- Deerfield Management's portfolio value fell 11% quarter-over-quarter to $2.5B.
Based on Deerfield Management's 13F filing for Q4 2018, filed 14 Feb 2019.